Skip to main content

Alnylam Announces Pandemic Flu as Next Development Program; Gets DoD Funding

NEW YORK, Dec. 14 (GenomeWeb News) - With initial funding from the Department of Defense, Alnylam Pharmaceuticals will advance its pandemic flu project into a development program, the company announced today.


The project will join the pipeline of other RNAi therapeutics. The company expects to submit an investigational new drug application for an RNAi therapeutic for pandemic flu as early as the end of 2006.


The funding came from DoD's Defense Advanced Research Projects Agency, Alnylam said. The amount was not disclosed.


The Alnylam pandemic flu program is focused on the development of an RNAi therapeutic targeting sequences that are highly conserved across all flu genomes, including those of avian origin such as the H5N1 strain.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.